Capivasertib 160 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 160 mg

Reference Brands: Truqap (USA)

Category: Oncology Cancer Care

Capivasertib 160 mg tablets are an AKT inhibitor used with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1 or PTEN changes. It is taken twice daily, four days on and three days off. It is made by AstraZeneca as Truqap and is a patented innovator product. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Capivasertib, also known by the brand name Truqap, is an oral targeted anticancer therapy used in combination with fulvestrant for the treatment of adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is specifically indicated for patients whose disease has progressed during or after prior hormone therapy and who have genetic alterations in the PIK3CA, AKT1, or PTEN genes.

Capivasertib works by selectively inhibiting AKT, a key protein involved in cell signaling pathways that regulate cancer cell growth, survival, and metabolism. By blocking AKT activity, capivasertib disrupts these pathways, helping to slow tumor growth and potentially induce cancer cell death. It belongs to the class of kinase inhibitors and represents an important advancement in precision oncology.

The drug is administered orally under specialist supervision and is being actively studied for use in other cancer types where AKT pathway abnormalities play a role. Capivasertib’s targeted mechanism allows for a more personalized treatment approach, offering improved outcomes for patients with specific molecular profiles while supporting long-term disease control in advanced breast cancer.